Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Acorda Therapeutics Inc
ACORQ
Healthcare
Biotechnology
Acorda Therapeutics, Inc. is a biopharmaceutical company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The Company markets Inbrija (levodopa inhalation powder), which is approved in the United States for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson’s disease treated with carbidopa...
/levodopa. Inbrija is not to be used by patients who take or have taken a nonselective monoamine oxidase inhibitor, such as phenelzine or tranylcypromine within the last two weeks. Inbrija utilizes its ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. ARCUS is a dry-powder pulmonary drug delivery technology. It also markets the branded AMPYRA (dalfampridine) extended-release tablets, 10 mg, to improve walking in adults with multiple sclerosis. Ampyra is marketed as Fampyra outside the United States by Biogen International GmbH.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (OTCPK:ACORQ)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
4
5
6
Next
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 27, 2022 7:08am
New Press Release - Acorda Therapeutics Provides Long-Term Business Plan and Financial Guidance
CEO video / Q&A with shareholders on October 28, 2022 to review business plan and ballot items for special meeting of stockholders Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a detailed, long-term business plan to drive shareholder value and also provided long-term financial...
read article.
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 25, 2022 4:01pm
New Press Release - Acorda Third Quarter 2022 Update: Webcast/Conference Call Scheduled for November 1, 2022
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a webcast/conference call in conjunction with its third quarter 2022 update and financial results on Tuesday, November 1 at 4:30 p.m. ET. To participate in the Webcast, please use the following registration link: https://event.on24.com/wcc/r...
read article.
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 21, 2022 3:50pm
ACOR ....No position ; )
Still on watch Waiting for the next shoe to drop Cheers !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 21, 2022 9:46am
ACOR ..... LoL....Now u get to hear the Director....
pull on all the Shareholders "heart strings".....Sheesh Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D. 2022-10-21 04:00 ET - News Release October 28,
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 21, 2022 7:01am
New Press Release - Acorda Shareholders Invited to Virtual Q&A with CEO Ron Cohen, M.D.
October 28, 2022 at 1pm ET, 10am PTShareholders are invited to submit questions to the CEO Acorda Therapeutics, Inc. (Nasdaq: ACOR) will hold a virtual, video Q&A with its CEO, Ron Cohen, M.D., on Friday, October 28 at 1:00pm ET, 10:00am PT. The call will review the items on the ballot for...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 20, 2022 8:33am
ACOR..It took a while but the 54 downside support failed ; )
Now trading at 51 in the PM open..... Now what? Make sure you vote your shares if you received your Proxies on Proposals 2 & 3 Another Reverse Split in the makings after the vote on Nov 04/22
...more
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 12:55pm
ACOR ..... u know your in trouble when......
the big bids start showing up..... This is going to be imploded shortly !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 12:48pm
ACOR ..... L.O.D
Cheers
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 12:34pm
ACOR ....ya still watching this Beotch ?
Pretty close to 54 now ...isn't it ; )
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 10:53am
ACOR ...... Cccccccrrrrrrrraaaaaacccccckkkkkkk !
The sound of ice breaking under your feet Wait for the 54
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 10:07am
ACOR ..... this will drop like f'king rock ...jmho
Wait for it
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 9:41am
ACOR ....don't fall for the bait & trap.....
1st support is ~ $0.54 Wait for it JMHO My Chartsing website is facked...as usual !
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 19, 2022 8:46am
ACOR ...... You've all been buried with high priced paper
Just like I mentioned in a previous post. Pretty amazing how they can manip the share price down before the NR 2 days ago and then the huge volume rally ensues Insiders seldom own shares when a RS
...more
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Oct 19, 2022 7:03am
New Press Release - ISS, Glass Lewis, and Egan-Jones Recommend that Acorda Stockholders Vote FOR the Proposal to Implement a Reverse Stock Split
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that the three leading, independent proxy advisory firms - Institutional Shareholder Services (ISS), Glass Lewis and Co, LLC, and Egan-Jones & Co - all recommend that shareholders vote “For” Proposal 2, Reverse Stock Split, at Acorda’s...
read article.
(72)
•••
Iseneschal
X
View Profile
View Bullboard History
Post by
Iseneschal
on Oct 18, 2022 1:22pm
ACOR ..... Not 2 bags !!!
I'll take that scalp any day 64 to 71.... Cha Ching ! Might do it again..... sub 70 ; ) A break of ~75 would be meaningful....but need some vol No break means "Range Bound for Bonzo"
...more
Prev
1
2
3
4
5
6
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >